CytomX Therapeutics, Inc.
Here’s whether CytomX Therapeutics, Inc. (CTMX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: 50-day MA is rising (+1.14% over 10 days); RSI 55 — healthy momentum range; strong 1-year return of +61.6%. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 3-month momentum negative (-12.8%). Currently 60.0% off its 52-week high. Score: -1/7.
CTMX is trading below its 200-day MA ($4.18) — a key warning sign the longer-term trend is under pressure. An RSI of 54.9 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +61.6% compares to +20.5% for SPY (beat the market by 41.1%). The current 60.0% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.